Abstract. Mitochondrial encephalomyopathies are under increasing consideration in the differential diagnosis of diverse metabolic diseases from infancy to late adulthood. This is to be expected considering the vital importance of mitochondria to cellular respiration in all eukaryotes, the vulnerability of the mitochondrial genome to injury, and the expanding appreciation of the role of mitochondria as a common denominator in cell death in ischemia/anoxia, sepsis, and neurodegenerative diseases. Primary disease of the mitochondrial respiratory chain is estimated to occur with an incidence of between 6 and 16/100,000 individuals. Virtually all tissues have been shown to be involved in diverse mitochondriopathies, but none is more appropriate for diagnosis in most cases than skeletal muscle. The conventional histological and ultrastructural diagnosis of mitochondrial disease in muscle has been increasingly supplanted by the biochemical assessment of respiratory chain enzyme deficiencies and definitive genetic diagnosis. The use of such techniques has afforded a greater understanding for the relative lack of specificity of both light and electron microscopic observations. A review of the current situation by placing muscle pathology in the context of biochemical and genetic diagnosis serves as a paradigm for the role of the pathologist in the molecular era.
INTRODUCTION
Mitochondria (mitos Gr. ''thread'' chondros Gr. ''granule'') (1) are of central importance in a wide diversity of human diseases. The high-energy demands of skeletal muscle predispose this tissue for frequent involvement in mitochondriopathies, and it is the tissue of choice for the pathological, biochemical, and genetic diagnosis of mitochondrial disease even if muscle is not predominantly involved. Given the protean manifestations of mitochondrial dysfunction, clinicians, pathologists and investigators are faced with the dilemma of distinguishing true mitochondrial encephalomyopathies from similar conditions. The pathologist is currently in the position of attempting a histological diagnosis in the midst of increasingly sophisticated molecular techniques in the enzymatic and genetic assessment of the mitochondrial respiratory chain. While muscle pathology and enzyme analysis may be sensitive in detecting mitochondrial disease, they lack the specificity afforded by a genetic diagnosis. However, genetic screening is known to detect only a small percentage of patients believed to have mitochondrial disease. It follows that the straightforward and definitive diagnosis of primary mitochondrial disease is a rarity.
The critical importance of mitochondria to cellular respiration involves a number of biological functions, including substrate transport, utilization including fatty acid oxidation and pyruvate oxidation, the Krebs cycle and the respiratory chain. This review is limited to mitochondrial disorders of oxidative phosphorylation and is intended to provide the diagnostic muscle pathologist an awareness of both the means and the limitations in diagnosing mitochondrial myopathies in an era when metabolic disease is increasingly defined in molecular terms.
Historical Aspects
Life on Earth would be drastically different had the ancestral mitochondrion not been engulfed by a larger anaerobic eukaryotic cell over one billion years ago. Mitochondria may have even become an essential organelle at the same time the nucleus was itself becoming a part of the eukaryote (2) . Mitochondria enabled the host cell to use oxygen in extracting the maximum amount of energy from food molecules. As the symbiotic relationship developed, the majority of the mitochondrial genome was to be transferred to the nuclear genome. Interestingly, the present day bacterium thought to be most closely related to the mitochondria's predecessor is Rickettsia prowazekii, the obligate intracellular pathogen causing typhus (3) .
Mitochondria were first recognized microscopically by Kölliker in 1857, and subsequently became the focus of 2 separate themes in modern biological research, cellular morphology and the respiration (4) . The fields were unified through the introduction of cell fractionation and electron microscopy in the mid-20th century. The subsequent studies of mitochondria by direct molecular approaches and sophisticated 3-dimensional structural analyses have resulted in the current detailed understanding of the enzymology of oxidative phosphorylation.
Mitochondrial DNA was not discovered until 1963 (5), although its existence had been surmised from special stains and respiration-deficient yeast in which defects were not transmitted by Mendelian laws. Rapid progress culminated in the publication of the complete nucleotide sequence of the human mitochondrial DNA in 1981 (6) .
As mitochondria became better understood in ultrastructural and functional terms, human disease attributable to mitochondria was to be recognized. In 1959, an abnormality of oxidative phosphorylation was discovered in a study of mitochondria isolated from thyrotoxic patients. A muscle biopsy from an euthyroid but severely hypermetabolic woman had large numbers of structurally abnormal mitochondria. The resulting case report from 1962 is commonly cited as the first example of a mitochondrial myopathy in which a biochemical abnormality of oxidative phosphorylation is described (7). This condition has now been recognized to be exceedingly rare along with the fact that structurally abnormal mitochondria are found in a host of disorders not associated with either a hypermetabolic state or defect of oxidative phosphorylation.
Prior to the molecular era, the emerging criteria for the diagnosis of mitochondrial disease relied upon the demonstration of mitochondrial proliferation by light microscopy and structurally abnormal mitochondria by electron microscopy. The advent in 1963 of the modified Gomori trichrome stain using cryostat sections of skeletal muscle led to the recognition of the ragged red fiber as the sine qua non of certain mitochondrial myopathies (8) . As further clinicopathological observations were made, it appeared that certain concomitant clinical and laboratory features constituted syndromes among mitochondrial encephalomyopathies, such as chronic progressive external ophthalmoplegia (CPEO), mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), and myoclonic epilepsy with ragged red fibers (MERRF), Leigh disease, etc.
Maternal inheritance in mitochondrial diseases was first recognized in 1988 in reports by Holt and Wallace. These reports contained the first direct evidence that mitochondrial DNA was involved in diseases, involving large deletions in mitochondrial myopathies (9) or a missense mutation in mitochondrial DNA from a patient with Leber's hereditary optic neuropathy (LHON) (10) . However, as increasing numbers of deletions and mutations of mitochondrial DNA were associated with these conditions, they were found to not always be uniquely associated with a particular clinical syndrome. This phenomenon is well exemplified by large heteroplasmic deletions, which may be associated with a broad diversity of clinical manifestations. While dosage and the differential segregation of wild-type and mutant mitochondria may explain differences between individuals bearing the same mitochondrial mutation, other mitochondrial or nuclear mutations may have secondary roles in the resulting clinical phenotype (11) . Epigenetic factors such as alcohol and tobacco use may also promote the onset of symptoms in disorders of homoplasmic missense mutations such as LHON. Currently, over 100 point mutations and well over 100 rearrangements of the mitochondrial genome have been associated with human disease. Developments in the field of human mitochondrial diseases may be accessioned through a database website http:// www.gen.emory.edu/mitomap.html.
Mitochondrial DNA is unlike nuclear DNA in several key respects. It is a circular 16,569 base pair double stranded DNA molecule (6) without DNA repair mechanisms or protective histones. The mitochondrial genome in humans is inherited maternally (12) . The mutation rate is more than 10 times that of nuclear DNA, probably related to the proximity of free radicals generated from oxidative phosphorylation. Because there are no introns in mitochondrial DNA, mutations will invariably affect a coding sequence. Mitochondrial DNA encodes 2 ribosomal RNAs, 22 transfer RNAs, and only 13 of the 84 subunits making up the respiratory chain (7 of 42 in Complex I, none of 4 in Complex II, 1 of 11 in Complex III, 3 of 13 in Complex IV, and 2 of 14 in Complex V). Some nuclear genes that do not code for respiratory chain protein subunits may also affect mitochondrial function, exemplified by the SURF-1, ANT, and SCO2 mutations.
Mitochondrial DNA is abundant, numbering 2 to 10 copies per mitochondrion (13) , with hundreds to thousands of mitochondria present in the cell (14) . In human skeletal muscle, they occupy about 4% of the total volume of the myofiber (15) . This feature has been used to great advantage in the fields of anthropology (16) and forensics (17) , whereby large numbers of essentially identical mitochondrial DNA copies may be the only remaining detectable species of nucleic acid in biological remains that are thousands of years old, or confer a ''fingerprint'' to limited remains of forensic relevance.
Since the mitochondrial respiratory chain is the only biochemical pathway in the cell under dual control by the nuclear and mitochondrial genomes, mitochondrial disease is currently viewed as due to 1 of 3 circumstances: a mitochondrial DNA mutation or deletion; nuclear mutations resulting in mitochondrial DNA alterations or defects in intergenomic signaling; or, Mendelian defects that affect the respiratory chain in the absence of mitochondrial DNA defects (18) .
More recently, mitochondria have been discovered to play an important role in cell death. Mitochondria are the major cellular source of reactive oxygen species. They can trigger apoptosis (19) , and mediate the effects of ischemia/anoxia (20) or sepsis (21) . Secondary mitochondrial dysfunction has been demonstrated in neurodegenerative conditions such as Parkinson (22) and Huntington diseases, and Friedreich's ataxia (23) . Knowledge of the extent to which the generation of reactive oxygen species and apoptosis are superimposed upon failure of energy production in mitochondrial encephalomyopathies will contribute to a more complete understanding of these diseases.
The Incidence of Mitochondrial Disease
The published literature of genetically confirmed mitochondrial diseases consists almost exclusively of single case or abnormal pedigree reports. The difficulties in prospectively studying large groups in order to ascertain the incidence of mitochondrial disease are obvious and would require considerable consensus regarding diagnostic criteria. As discussed above, the only readily available testing is for known mitochondrial mutations but not nuclear DNA mutations. In some diseases the mutation may be difficult or impossible to detect in peripheral blood, therefore requiring a muscle biopsy. The problem is further compounded by the gradual accumulation of mitochondrial mutations with age, although of potential significance in neurodegenerative and other diseases of aging. The only studies addressing the incidence of mitochondrial disease have relied upon the referral of patients for neurological evaluation from a relatively stable population base. A 7-year prospective survey in Finland of 116 children with unexplained psychomotor retardation derived from a pediatric population base of over 97,000 arrived at an incidence of 17/116 by biochemical criteria and only 1 was shown to have a pathogenic mitochondrial DNA mutation (24) . Studies in adults have suggested a higher prevalence. In England, adults with suspected mitochondrial disease were accrued over a 10-year period. Based upon genetic and statistical analyses, the authors concluded that 6.57 per 100,000 adults (roughly the same incidence as Huntington disease or brain tumors in adults), and overall, 12.48 children and adults per 100,000 individuals either had or were at risk of developing mitochondrial disease (25) . A study of the A3243G mutation in a Finnish cohort selected for commonly associated features of MELAS yielded a calculated frequency of Ն16.3/100,000 (26).
The Diagnosis of Mitochondrial Myopathies
Clinical: The expanding spectrum of disease manifestations associated with disorders of the mitochondrial respiratory chain and frequently used eponyms is summarized in Table 1 . It is not within the scope of this review to correlate all known manifestations of defective mitochondrial oxidative phosphorylation with muscle pathology. However, it is worth noting that certain clinical syndromes may direct the rationale in choosing a diagnostic method. For example, in LHON there is a homoplasmic missense mitochondrial DNA mutation distributed in all tissues. Therefore in LHON, blood mitochondrial DNA analysis is likely to be diagnostic, even in asymptomatic maternal relatives. . D: Absent COX activity in scattered fibers from a case of COX deficiency in a 14-day-old male. Note that ragged red fibers are never seen in infancy or early childhood, and in older patients COX-negative fibers may outnumber ragged red fibers. (Cryostat section, COX enzyme histochemistry. 400X). E: Electron micrograph showing subsarcolemmal accumulation of abnormal mitochondria with crystalloid inclusions and admixed glycogen from a 21-year-old male with progressive external ophthalmoplegia and ragged red myopathy. (6500X). F-I: Examples of mitochondrial proliferation with no demonstrable respiratory chain enzyme deficiency: Serial sections from muscle of a 5-year-old male with mild developmental delay and hypotonia, with mitochondrial proliferation by light and electron microscopy seen as mildly increased subsarcolemmal staining (arrows) in the trichrome (F), SDH (G), and COX (H) enzyme histochemistries, corroborated by significant elevation in citrate synthase, but with normal respiratory chain enzyme activities. (400X). I: Electron micrograph of abnormally enlarged mitochondrion and prominent lipid in the muscle of a 7-year-old female with severe cardiomyopathy, with mitochondrial proliferation but normal respiratory chain enzyme activities. (7000X).
Light Microscopy: As in any myopathy, cryostat sections provide the essential means for the accurate morphological analysis of individual myofibers. The ragged red fiber (Fig. 1A) is usually readily recognizable, but worth understanding in terms of its morphogenesis. The ragged red fiber and its neighboring myofibers in affected skeletal muscle may be seen as a microcosm of mitochondrial disease. Myofibers may vary among themselves as they do with other cell types in the endowment of mitochondria, owing to the segregation of both normal and genetically abnormal mitochondria from the point of division of the oocyte. Mutations in the somatic cell mitochondrial genome in early embryogenesis can also give rise to apparently exclusive involvement of 1 tissue type. If the differentiated cell contains a homogeneous population of either normal or abnormal mitochondria, the condition is referred to as homoplasmy, and if a mixture of genetically distinct mitochondria exists within a single cell, the condition is referred to as heteroplasmy. In vitro studies have shown that a biochemical defect of mitochondrial function is expressed only when a critical percentage level of mutated mitochondrial DNA is exceeded. This threshold varies from tissue to tissue, in part related to the degree to which a particular organ depends upon oxidative metabolism. If in the case of a skeletal myofiber, mitochondrial dysfunction triggers mitochondrial proliferation to the extent that the characteristic subsarcolemmal red staining occurs with the Gomori trichromestained cryostat section, this fiber may be assumed to be heteroplasmic with a threshold percentage of at least 85% abnormal mitochondrial DNA (27) , although estimates may vary in this regard.
It is important to realize that ragged red fibers occur in only certain mitochondrial myopathies. They are most common in defects of mitochondrial protein synthesis such as in the eponymic condition MERRF, in which a point mutation occurs in the mitochondrial DNA gene for lysine-transporting tRNA. The frequency of ragged red fibers may vary between less than 1 to more than 30% of fibers (28) . Ragged red fibers are distinctly uncommon in a number of mitochondrial myopathies. For example in patients with Complex I deficiencies, perhaps the most common cause of Leigh syndrome, they have never been reported in nuclear encoded and rarely in mitochondrial DNA encoded Complex I deficiency (29) . Although the medical and scientific literature does not provide a definitive statement in this regard, anecdotal experience with an excess of 100 pediatric muscle biopsies in mitochondrial diseases has never revealed their presence in patients less than 3 years of age. At the other end of the age spectrum, ragged red fibers may be seen with ''normal'' aging and may comprise 0.4% of myofibers by the eighth decade (30) .
Although ragged red fibers have been described in a variety of conditions including adult acid maltase deficiency, other myopathies, and with aging, their presence in the proper clinical context is strong evidence for a mitochondrial myopathy (28) . The predominantly subsarcolemmal accumulation of mitochondria observed in the ragged red fiber may be seen as increased subsarcolemmal activity for NADH dehydrogenase, succinate dehydrogenase (SDH), and cytochrome c oxidase (COX) if the synthesis of the respective enzyme is not affected by the mutation. In particular, an increase in vascular smooth muscle SDH activity may be a useful indicator of mitochondrial proliferation, particularly in MELAS (Fig. 1B) . The converse is not necessarily the case: in a case of Complex II deficiency, SDH activity was nearly absent in muscle fibers but preserved in intramuscular blood vessels (31) .
The assessment of SDH and COX activity in fibers known to be ragged red in adjacent sections can be of further diagnostic importance, as well as in fibers without ragged red morphology. In fact, COX-deficient fibers may outnumber ragged red fibers (32) of an infant or young child (Fig. 1D) . If a ragged red fiber shows strong subsarcolemmal SDH activity (the socalled ''ragged blue fiber'') (33) (Fig. 1B) and COX negativity, disorders stemming from mitochondrial DNA deletions or tRNA mutations resulting in defective mitochondrial protein synthesis (i.e. MERRF, KearnsSayre syndrome [KSS], or CPEO) should be considered. Alternatively, ragged red fibers with strong SDH activity that are COX-positive are characteristic of MELAS or in cases of mutations in mitochondrial structural genes, except in COX genes. If COX activity is diffusely decreased but sparing muscle spindles and vascular smooth muscle, diagnostic considerations should include both the fatal and benign forms of infantile COX-deficient myopathy. The presence of COX activity in all fibers does not rule out COX deficiency. Interestingly, COX-negative fibers have been seen in increasing numbers with aging, paralleling the age-related increase in ragged red fibers, and may be seen in inflammatory myopathies, including inclusion body myositis (34) .
The pathologist may be confronted by neither ragged red fibers nor COX-deficient fibers, but may nonetheless note evidence of mitochondrial proliferation. In the Gomori trichrome stained myofiber there may be a thin red border of subsarcolemmal red staining (Fig. 1F) , confirmed to be mitochondrial by increased subsarcolemmal staining with the SDH (Fig. 1G) , and sometimes COX enzyme histochemical preparations (Fig. 1H) . While mitochondrial proliferation may be readily identified by light microscopy, its predictive value specifically for respiratory chain deficiencies is doubtful. In a series of muscle biopsies done for suspected mitochondrial myopathy and submitted for respiratory chain enzyme analysis, mitochondrial proliferation was actually more frequent in samples found to have normal respiratory chain activities (35) . These may reflect mild impairment of the mitochondrial respiratory chain, but there are alternative explanations for secondary mitochondrial proliferation in the absence of mitochondrial mutations such as anticonvulsants (36), neurogenic atrophy (37), and corticosteroid and thyrotoxic myopathies (38) .
It may be relevant in mitochondrial myopathies to test for excessive glycogen (PAS with and without diastase) and neutral lipid accumulation (Oil red O) (Fig. 1C) . Glycogen and lipid accumulations do not carry diagnostic specificity but may be useful in excluding primary glycogen or lipid storage disorders. Also, lipid storage in ragged red fibers may suggest CoQ 10 deficiency, COX deficiency, or KSS.
Formalin-fixed tissue is of very limited usefulness in the initial pathological evaluation of a suspected but undiagnosed mitochondrial myopathy. Therefore if tissue is limited, which is often the case in infants, this may be omitted. However, in documented mitochondrial myopathies, certain elegant approaches may be taken to localize normal or mutated mitochondrial DNA or abnormal enzyme subunits. For example, in Complex IV deficiency, it may be useful to employ antibodies directed against either nuclear or mitochondrially encoded Complex IV subunits in order to determine the particular type of deficiency (39), yielding prognostic implications of diagnosing the fatal versus benign forms of infantile COX deficiency. Such antibodies are currently becoming commercially available, and thereby not only afford the opportunity for a detailed dissection of COX deficiency by analyzing component subunit deficiencies, but also add the possibility of studying archival paraffin-embedded materials.
A number of other specialized and novel techniques have been developed to characterize the abnormal histology of mitochondrial myopathies that may be beyond the routine pathological assessment of a possible mitochondrial myopathy. Noteworthy are the achievements of Bonilla and his colleagues in the use of enzyme histochemistry, fluorescent probes for mitochondria, membrane phospholipids and lipid droplets, immunohistochemistry (40) , and in situ hybridization (41) . Studies of single myofibers utilizing the polymerase chain reaction have been proved useful in detecting and indicating pathogenicity of mitochondrial DNA mutations in abnormal fibers when they are outnumbered by fibers with wildtype mitochondrial DNA (42) .
The pathologic diagnosis of a mitochondrial myopathy requires special handling of a biopsy. The specimen must be obtained by a surgeon with experience and an awareness that the biopsy need be free of cautery, excessive manipulation, and of a size adequate for cryotomy, electron microscopy, and biochemical and genetic analysis. The latter require at least 100 mg of tissue and preferably 2 to 3 times as much. It is preferable that respiratory chain enzyme testing be done on tissue dedicated for that purpose rather than relying upon frozen tissue already used for cryotomy. One source suggests that isopentane, commonly used in snap freezing of muscle and other tissues to avoid freeze artifact, may have ''detrimental effects'' on respiratory chain activities (43) .
Electron Microscopy: Despite the historical importance of electron microscopy in correlating morphological abnormalities of mitochondria with clinical and other pathologic findings, a contemporary approach to diagnosis of mitochondrial myopathies in the molecular era must bring into question lack of specificity and the expense of determining ultrastructural abnormalities of mitochondria. Enlarged and abnormally shaped mitochondria (Fig.  1I) are typical of mitochondrial myopathies but may be seen in virtually all myopathies including dystrophic, inflammatory, diverse metabolic and even neuropathic diseases. In mitochondrial disease, abnormalities include sparse, concentric, or bizarre cristae (44) . Mitochondrial crystalloid inclusions (Fig. 1E ) occur in the intermembranous space and are immunoreactive for antibodies to mitochondrial creatine kinase (45) . They may also be found in other myopathies and as an incidental finding in otherwise normal muscle (46) . They should not be confused with the plate-like inclusions in cristae seen in anoxic or postmortem muscle (44) . While their presence in cases with ragged red fibers is strongly supportive of a mitochondrial myopathy, crystalloid inclusions and morphological abnormalities of cristae offer little insight into the responsible biochemical or genetic defect.
Respiratory Chain Enzymology: The contemporary pathologic diagnosis of a metabolic myopathy, including mitochondrial myopathies, ultimately hinges upon the results of testing for the enzyme in question by biochemical means. Skeletal muscle is the tissue of choice for this purpose because of its accessibility and dependence upon oxidative metabolism. Furthermore, respiratory chain deficiencies are not frequently expressed in cultured fibroblasts (47) . Of the 5 Complexes comprising the respiratory chain, I through IV may be tested in suitably preserved frozen muscle, while Complex V (ATP synthase) may only be assayed using mitochondria extracted from a fresh sample of skeletal muscle. Various other intermediaries in oxidative phosphorylation, such as Coenzyme Q, are not directly studied by respiratory chain enzymology.
A minimum of 25 milligrams of tissue is required for each assay, and with the occasional desirability of confirmation through repeated testing, a minimum of 150 mg (roughly equivalent to a size of approximately 5 mm 3 ) is required for testing of Complexes I through IV. An excess of fibrous or adipose tissue, or of Type 2 myofibers may limit the usefulness of the biopsy. Regarding the use of autopsy tissue, the inevitable decline of respiratory chain enzyme activity must be kept in mind; activity of Complex I in brain has been determined to decrease approximately 9.5% per hour. Meaningful studies using autopsy muscle are not likely with a postmortem interval of greater than 4 hours, and specimens are preferably obtained within 1 hour of death.
For the correct assessment of enzyme deficiencies a reference enzyme activity is typically determined, usually of citrate synthase. This may serve as an indicator of mitochondrial proliferation even in the absence of respiratory chain defects and determine whether respiratory chain activities must be corrected. When abnormal, results will be reported as indicating discreet deficiencies of Complexes I, II, III, or IV, or I-III or I-II, which may be interpreted as indicators of Coenzyme Q 10. Several important considerations should be borne in mind when placing respiratory chain enzyme testing results in the context of clinical and pathological features: 1) Considerable residual enzyme activities are typically found with patients with respiratory chain defects. Therefore, since activities are never completely absent, varying degrees of deficiency must be assigned arbitrarily, a concept seemingly at odds with the quantification of enzyme activities. 2) Enzyme testing may be confounded by enzyme deterioration if samples are not frozen in a timely manner, other variables in the testing conditions, and a surprising variability in reproducibility. 3) Control values have not been widely standardized, an important consideration since respiratory chain activities may vary significantly with age. For example, respiratory chain activity has been noted to decrease with age in human skeletal muscle and liver mitochondria along with ultrastructural changes. In isolated mitochondria, COX activity shows a 50% decrease between 4 and 19 years (48). 4) Normal respiratory chain activities may be seen in otherwise proven mitochondrial myopathies, and conversely, marked deficiencies in respiratory chain enzyme activities may be seen in other metabolic myopathies such as glycogen storage disease, Zellweger syndrome, Menkes disease, and numerous others.
Regardless of these considerations, the type of Complex deficiency or pattern of combined deficiencies may ultimately represent the most sensitive if not the most specific means of diagnosing a mitochondrial Table  3 . Complex I deficiency is probably the single most common respiratory chain enzyme deficiency. Accordingly, isolated Complex I deficiency is one of the most common causes of mitochondrial encephalomyopathies, including Leigh syndrome (49, 50) . The A3243G MELAS mutation is associated with Complex I deficiency (51) but may also result in Complex IV or combined I-IV deficiency (52) (53) (54) . Three separate mutations have been associated with decreased Complex I activity and LHON (55) . Mutations in protein coding genes may also cause isolated Complex I deficiency. Complex I deficiency may be reliably diagnosed in muscle, and in some cases using other affected tissues or even cultured fibroblasts (29) . Complex II is the only subunit to be entirely nuclear encoded. Deficiencies have been associated with Leigh syndrome and a wide spectrum of other disorders although only 3 pathogenic mutations in Complex II genes have been identified (56) . Interestingly, one mutation is found in hereditary paraganglioma, the first example of a respiratory chain gene error causally associated with neoplasia (57).
Complex III deficiency has been documented in a condition of severe exercise intolerance and lactic acidosis in the resting state (58) . The condition serves as an example of how a mitochondriopathy may reside exclusively in muscle and may not be diagnosable with other tissues. Complex IV (COX) deficiency usually manifests as an autosomal recessive disease and may present in a variety of distinct ways, including Leigh syndrome, fatal infantile cardioencephalomyopathy, or the KSS. Complexes I-III or I-II deficiencies may signify Coenzyme Q 10 deficiency, characterized by delayed milestones, proximal weakness, ataxia, and exercise intolerance, with ragged red fibers with excessive lipid by muscle biopsy. Combined partial deficiency of Complexes I, III, and IV is likely to be the result of multiple mitochondrial DNA deletions or mitochondrial DNA depletion.
Mitochondrial Mutational Analysis: Many muscle biopsies in the diagnosis of mitochondrial myopathies will be intended for mitochondrial mutational analysis. Specialized laboratories offer testing for an increasing number of mitochondrial mutations and deletions, but as yet not for nuclear encoded mitochondrial gene mutations. It is not surprising that the positive yield from genetic screening is low, even in cases with documented respiratory chain enzyme deficiencies, ranging from less than 1% (24) to 4% (59) in children to up to one third of adults with clinically recognizable mitochondriopathies (59) . Another study of 2000 specimens, mostly blood samples, from a predominantly pediatric population yielded a positive detection rate of 5.9% using a multiplex polymerase chain reaction-allele specific oligonucleotide method testing for 44 point mutations (60) . Nevertheless, the diagnostic significance and importance to genetic counseling mandate the use of a portion of the frozen muscle for mitochondrial mutational analysis. Reference laboratories providing this service typically require at least 50 mg of snap frozen tissue. Table 4 summarizes the categories of mitochondrial and nuclear mutations associated with respiratory chain enzyme deficiencies.
Future Prospects
The diagnosis of diseases with the overwhelming diversity and complexity of the mitochondriopathies will always require a multi-disciplinary approach. As mitochondria are linked with an ever-widening array of tissue or organ dysfunction ranging from skin disease to depression, pathologists will receive muscle biopsies only in part to render a histological diagnosis but rather with the ultimate goal of molecular testing. The number of known mitochondrial DNA mutations and deletions has been increased to the extent that multigene array testing may represent an appropriate approach in detecting these genetic abnormalities. The Human Genome Project may serve to expand knowledge of the nuclear genome of mitochondria thereby enabling the discovery of what will ultimately be the majority of gene defects underlying mitochondrial diseases. The field lacks effective experimental animal models, and species differences in mitochondria may represent a formidable obstacle in this regard.
The recently developed mouse model of mitochondrial disease created by populating oocytes with mitochondria harboring a DNA deletion differs significantly from the predicted human phenotype of Kearns-Sayre syndrome (38) , thus illustrating the problems posed by species differences in the organization and distribution of mitochondrial DNA but has nonetheless been regarded as an important advance.
Summary
The advent of molecular diagnosis is now superimposed upon the bewildering array of often nonspecific clinical and pathologic findings in suspected cases of mitochondrial myopathy. The biochemical assessment of mitochondrial respiratory chain enzyme activities, as well as mitochondrial mutational analysis, are now readily available to the pathologist specializing in muscle pathology. As a paradigm for the emerging importance of biochemical and genetic definition of human metabolic diseases, the pathologist must be circumspect in relying upon the presence or lack of classical features, as well as in interpreting nonspecific abnormalities, particularly when diagnostic confirmation currently resides in biochemical and mutational analyses. Respiratory chain and mutational analyses are also prone to inconclusive results but provide the promise of a better understanding of the pathogenesis in mitochondrial diseases.
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